Glaucoma may be a significant predictor of depression, according to research published in the American Journal of Ophthalmology.
Ophthalmology Times Staff Reports
The FDA approved OptiMedica's Catalys Precision for creating single-plane and multi-plane arc incisions in the cornea during cataract surgery.
Glaucoma and age-related macular degeneration (AMD) research grants have been awarded to Wilmer Eye Institute by the American Health Assistance Foundation.
Researchers have identified the mode of death of cone photoreceptor cells in an animal model of retinitis pigments (RP).
The Welch Allyn facility in Beaverton, OR, earned Leadership in Energy and Environmental Design (LEED) certification from the U.S. Green Building Council.
William M. Moore has been named interim president and chief executive officer of Iridex Corp. Moore succeeds Dominik Beck.
Ocular Therapeutix Inc. is initiating a phase II clinical trial of OTX-TP2, a 2-month travoprost punctum plug for treating ocular hypertension and glaucoma.
Gevokizumab, an IL-1 beta-modulating antibody from XOMA Corp., has received FDA orphan drug designation for the treatment of several types of non-infectious uveitis.
The Foundation Fighting Blindness is funding projects related to age-related macular degeneration, retinitis pigmentosa, Leber's congenital amaurosis, and Usher syndrome.
Ophthalmologists will have a new way to learn about advances in laser surgery next year, thanks to a $1 million donation made to the American Academy of Ophthalmology.